澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

IMMURON LTD

0.037

0.000

成交量：- -

成交額：- -

市值：1,194.54萬

市盈率：-2.02

高：0.037

開：0.037

低：0.037

收：0.037

52周最高：0.098

52周最低：0.026

股本：3.23億

流通股本：2.65億

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.018

每股收益(LYR):-0.023

淨資產收益率：-39.68%

總資產收益率：-21.93%

市淨率：0.91

市盈率(LYR):-1.64

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股+2.85%

資金流向

資金流入：

資金流出：

新聞資訊

IMMURON LTD作出戰略決策：尋求合作伙伴為Travelan與IMM-529臨床項目提供資金支持

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/IMC.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.037,"timestamp":1787638320000,"preClose":0.037,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"IMMURON LTD","floatShares":265374293,"shares":322848081,"eps":-0.018314,"marketStatus":"未開盤","change":0,"latestTime":"08-25 16:12:00 AEST","open":0.037,"high":0.037,"low":0.037,"amount":0,"amplitude":0,"askPrice":0.037,"askSize":52543,"bidPrice":0.034,"bidSize":271700,"shortable":3,"etf":0,"ttmEps":-0.018314,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.037,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMC.AU","preClose":0.034,"auctionPrice":0.037,"auctionVolume":3774,"auction":3,"marketStatus":"盘后竞价","timestamp":1787551547694}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":265374293,"roa":"-21.93%","roe":"-39.68%","lyrEps":-0.022586,"shares":322848081,"dividePrice":0,"high":0.037,"amplitude":0,"preClose":0.037,"low":0.037,"week52Low":0.026,"pbRate":"0.91","psRate":"1.60","week52High":0.098,"institutionHeld":0,"latestPrice":0.037,"committee":0.675904,"eps":-0.018314,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.018314,"open":0.037,"prevYearClose":0.036,"prevWeekClose":0.034,"prevMonthClose":0.036,"prevQuarterClose":0.033,"fiveDayClose":0.039,"twentyDayClose":0.037,"sixtyDayClose":0.047},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1138357123","title":"IMMURON LTD作出戰略決策：尋求合作伙伴為Travelan與IMM-529臨床項目提供資金支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1138357123","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138357123?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 19:12","pubTimestamp":1772017927,"startTime":"0","endTime":"0","summary":"IMMURON LTD宣布已制定关键战略方针，将通过寻求外部合作的方式为旗下两款核心产品——Travelan与IMM-529的临床研究计划注入资金动力。该决策旨在加速推进两项临床项目的研发进程，同时优化公司资源分配结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMC.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.0285}]}}